




Searching News Database: methylphenidate
HSMN NewsFeed - 27 Jun 2019
DURECT Announces Submission to FDA of a Full Response to the POSIMIR(R) Complete Response Letter
DURECT Announces Submission to FDA of a Full Response to the POSIMIR(R) Complete Response Letter
HSMN NewsFeed - 30 Apr 2019
Lannett To Launch Generic Concerta(R), AB-rated Methylphenidate Hydrochloride ER Tablets
Lannett To Launch Generic Concerta(R), AB-rated Methylphenidate Hydrochloride ER Tablets
HSMN NewsFeed - 31 May 2018
Cingulate Therapeutics Strengthens Leadership with Two New Board Appointments
Cingulate Therapeutics Strengthens Leadership with Two New Board Appointments
HSMN NewsFeed - 7 May 2018
ANI Pharmaceuticals Completes Acquisition of Generic Products and Assets from Amneal/Impax
ANI Pharmaceuticals Completes Acquisition of Generic Products and Assets from Amneal/Impax
HSMN NewsFeed - 10 Jul 2017
Cingulate Therapeutics Appoints Strategic Finance Veteran Louis G. Van Horn as Chief Financial Officer
Cingulate Therapeutics Appoints Strategic Finance Veteran Louis G. Van Horn as Chief Financial Officer
HSMN NewsFeed - 24 Feb 2017
Intellipharmaceutics Announces FDA Approval for 500 mg and 750 mg Generic Glucophage(R) XR
Intellipharmaceutics Announces FDA Approval for 500 mg and 750 mg Generic Glucophage(R) XR
HSMN NewsFeed - 27 Nov 2015
Lannett Completes Major Acquisition Of Kremers Urban Pharmaceuticals For $1.23 Billion
Lannett Completes Major Acquisition Of Kremers Urban Pharmaceuticals For $1.23 Billion
HSMN NewsFeed - 14 Sep 2012
Impax Laboratories Announces Settlement of Litigation Relating to CONCERTA(R)
Impax Laboratories Announces Settlement of Litigation Relating to CONCERTA(R)
HSMN NewsFeed - 16 Mar 2009
Shire Withdraws European Application for DAYTRANA(TM) (Methylphenidate Transdermal System)
Shire Withdraws European Application for DAYTRANA(TM) (Methylphenidate Transdermal System)
HSMN NewsFeed - 20 Feb 2009
Shire to Enter European ADHD Market With the Acquisition of EQUASYM(R) IR and XL
Shire to Enter European ADHD Market With the Acquisition of EQUASYM(R) IR and XL
HSMN NewsFeed - 29 Apr 2008
Noven Appoints Peter C. Brandt as President, Chief Executive Officer & Director
Noven Appoints Peter C. Brandt as President, Chief Executive Officer & Director
HSMN NewsFeed - 26 Dec 2007
Noven Announces FDA Tentative Approval of Stavzor(TM) Valproic Acid Delayed Release Capsules
Noven Announces FDA Tentative Approval of Stavzor(TM) Valproic Acid Delayed Release Capsules
HSMN NewsFeed - 30 Oct 2007
New Therapies Emerging to Challenge Pain Management for Transdermal Patch Growth
New Therapies Emerging to Challenge Pain Management for Transdermal Patch Growth
HSMN NewsFeed - 23 Oct 2007
FDA Issues Approvable Letter for Stavzor(TM) Delayed Release Valproic Acid Capsules
FDA Issues Approvable Letter for Stavzor(TM) Delayed Release Valproic Acid Capsules
HSMN NewsFeed - 29 Jun 2007
Shire Announces Filing of VYVANSE(TM) (Lisdexamfetamine Dimesylate) for the Treatment of ADHD in Adults
Shire Announces Filing of VYVANSE(TM) (Lisdexamfetamine Dimesylate) for the Treatment of ADHD in Adults
HSMN NewsFeed - 26 Oct 2006
DAYTRANA(TM) (methylphenidate transdermal system) Provides Individualized Symptom Management
DAYTRANA(TM) (methylphenidate transdermal system) Provides Individualized Symptom Management
HSMN NewsFeed - 29 Jun 2006
Noven Confirms Availability of Daytrana(TM) Methylphenidate Transdermal System
Noven Confirms Availability of Daytrana(TM) Methylphenidate Transdermal System
HSMN NewsFeed - 25 May 2006
Significant ADHD Symptom Control With Shorter DAYTRANA(TM) (methylphenidate transdermal system) Wear Time
Significant ADHD Symptom Control With Shorter DAYTRANA(TM) (methylphenidate transdermal system) Wear Time
Additional items found! 54

Members Archive contains
54 additional stories matching:
methylphenidate
(Password required)
methylphenidate
(Password required)